Pneumocystis pneumonia during everolimus therapy for Kasabach-Merritt phenomenon

Pediatr Int. 2023 Jan-Dec;65(1):e15593. doi: 10.1111/ped.15593.

Authors

Kohei Otomi¹, Ai Yamada¹, Jun Kurogi¹, Sachiyo Kamimura¹, Hiroshi Moritake¹

Affiliation

¹ Division of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

PMID: 37615371
DOI: 10.1111/ped.15593

No abstract available

Keywords: Kasabach-Merritt phenomenon; everolimus; immunological evaluation; pneumocystis pneumonia; prednisolone.

MeSH terms

Everolimus / adverse effects
Humans
Kasabach-Merritt Syndrome*
Pneumonia, Pneumocystis* / diagnosis
Pneumonia, Pneumocystis* / drug therapy
Prednisolone
Sirolimus / adverse effects

Substances

Everolimus
Sirolimus
Prednisolone